OrbiMed’s Assembly Biosciences ASMB Stock Holding History

OrbiMed’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-43,633	Closed	-$7.06M	–	121
2019 Q2	$7.06M	Sell	43,633 -39,377	-47%	-$7.48M	0.11%	98
2019 Q1	$19.6M	Hold	83,010	–	–	0.3%	75
2018 Q4	$22.5M	Sell	83,010 -19,771	-19%	-$5.72M	0.42%	65
2018 Q3	$45.8M	Buy	102,781 +42,684	+71%	+$20M	0.55%	57
2018 Q2	$28.3M	Hold	60,097	–	–	0.34%	70
2018 Q1	$35.4M	Sell	60,097 -39,739	-40%	-$24.6M	0.44%	61
2017 Q4	$54.2M	Buy	99,836 +37,500	+60%	+$17M	0.69%	45
2017 Q3	$26.1M	Sell	62,336 -11,700	-16%	-$3.59M	0.25%	78
2017 Q2	$18.3M	Sell	74,036 -30,739	-29%	-$8.66M	0.19%	80
2017 Q1	$32M	Sell	104,775 -11,650	-10%	-$2.86M	0.36%	64
2016 Q4	$17M	Hold	116,425	–	–	0.22%	73
2016 Q3	$10.1M	Hold	116,425	–	–	0.11%	100
2016 Q2	$7.75M	Hold	116,425	–	–	0.08%	101
2016 Q1	$7.01M	Hold	116,425	–	–	0.07%	105
2015 Q4	$10.5M	Hold	116,425	–	–	0.1%	91
2015 Q3	$13.4M	Hold	116,425	–	–	0.13%	84
2015 Q2	$26.9M	Buy	116,425 +3,925	+3%	+$757K	0.22%	73
2015 Q1	$17.9M	Buy	+112,500	New	+$15.2M	0.15%	84

Other funds holding ASMB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed's ASMB Position: Q3 2019 in Review

OrbiMed sold out of Assembly Biosciences (ASMB) in Q3 2019, closing a stake of 43,633 shares — an estimated $7.06M sold.

OrbiMed first reported a position in ASMB in Q1 2015 and held it in 18 quarters. The position peaked at $54.2M in Q4 2017. 98 funds tracked by Wall St. Rank hold ASMB as of Q3 2019.

OrbiMed reported no remaining Assembly Biosciences position as of Q3 2019 after selling out during the quarter.
OrbiMed sold 43,633 Assembly Biosciences shares in Q3 2019, an estimated $7.06M.
OrbiMed first reported a position in Assembly Biosciences in Q1 2015 and held it in 18 quarters.
OrbiMed's Assembly Biosciences position peaked at $54.2M in Q4 2017.
98 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2019.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.